Guangzhou Baiyunshan completes 5th receivables sale, boosts working capital

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced the sale of a fifth batch of newly added basic assets, consisting of accounts receivable with a book value of 441,632,185.38 yuan, to Everbright Securities Asset Management Co., Ltd. The transaction, completed on November 28, 2025, generated proceeds of 440,280,622.20 yuan. This marks the latest in a series of asset sales under the fourth phase of the Basic Asset Purchase and Sale Agreement.

This "Transaction AA," combined with four prior transactions totaling 1,981,855,364.57 yuan, brings the total purchased receivables to 2,478,927,083.58 yuan, yielding total proceeds of 2,450,818,611.84 yuan. The difference of approximately 0.28 billion yuan will cover financing costs and taxes. The proceeds are intended to supplement Guangzhou Pharmaceutical's working capital.

Given the aggregate nature of these transactions, all occurring within a 12-month period and being similar in nature, they are consolidated for reporting purposes. The total maximum applicable percentage ratio for the combined transactions is over 5% but less than 25%, classifying it as a discloseable transaction under Chapter 14 of the Listing Rules, requiring reporting and announcement.